Fecal microbiota transplant (FMT) is a promising option for patients struggling with CDI recurrences. But how can we ensure the treatment is successful?
Although COVID-19 vaccination remains the primary focus for health care, other paramount vaccines need to be recognized. Here is a review.
Here is a review of the effectiveness of fidaxomicin vs vancomycin for CDI treatment in populations with immunocompromised conditions.
Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.
Important clinical considerations to know about resistant CMV infections.
In the current state of the mpox outbreak, individuals with advanced HIV face a higher risk of severe illness, making vaccination and targeted public health measures essential.
Experts provide practice pearls for educating patients on and using FMTs for the management of CDI.
Salmonella becomes more dangerous as antimicrobial resistance grows. Read about its most common manifestations.
Clinicians review a patient case including diagnosis, treatment, and follow-up.
Despite hepatitis C (HCV) incidence rates increasing, adequate screening for the virus continues to be a pressing challenge for public health officials.
In the latest Bench to Bedside column, 2 clinicians discuss the benefits of utilizing social media for learning.
Expert hepatologists discuss future developments in HCV that they are excited about and provide resources for new providers to get started on delivering HCV care.
Lack of data may mean bloodstream infections caused by PVCs are an overlooked cause of morbidity in hospitalized patients.
A multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.
The increase highlights the threat posed by climate change and the need for innovative preparedness, prevention, and mitigation tools.
Rates of hospital-onset multidrug-resistant P aeruginosa infections have increased significantly in recent years.
Here is a review of using this therapy in this patient population.
This year's Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing provided updated breakpoints on therapies.
In the third installment of our series on injectables, long-acting injectables offer new treatment and prevention options for HIV, especially benefiting patients who struggle with daily oral medications.
With potential delays in treatment, bloodstream infections can be concerning for clinicians. Here is a review of the literature that offer guidance for treatment.
Our panel discusses this patient group and the challenges associated with their care.
Expert hepatologists discuss future developments in HCV that they are excited about and provide resources for new providers to get started on delivering HCV care.
Rare cases of health care–associated meningitis and ventriculitis in adults caused by Candida species are associated with recent bacterial meningitis and broad-spectrum antibiotic use.
This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.
A review of treatment modalities for this patient population.
Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.
Experts share advice for physicians taking care of patients with C. difficile infection (CDI).
This is a challenging pathogen, requiring pharmacokinetic and pharmacodynamic considerations; the recent FDA approval of sulbactam-durlobactam offers new hope.
Infectious disease outbreaks will continue to increase and trying to find strategies to ensure providers are cared for to prevent burnout and shortage staffing is essential if another pandemic arises.